Serum VEGF levels in the early diagnosis and severity assessment of non-small cell lung cancer
Yanzhen Lai, Xueping Wang, Tao Zeng, Shan Xing, Shuqin Dai, Junye Wang, Shulin Chen, Xiaohui Li, Ying Xie, Yuan-Ying Zhu, Wanli Liu · Journal of Cancer · 2018
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2018
Abstract
Background: Effective biomarkers are essential to the differential diagnosis and severity assessment of non-small cell lung cancer (NSCLC).This study explored the use of the serum vascular endothelial growth factor (VEGF) levels as a biomarker with the aim of achieving better management of NSCLC.Methods: Serum VEGF levels were assayed via enzyme-linked immunosorbent assay in 180 patients with NSCLC, 136 patients with benign pulmonary nodules, and 119 healthy controls.We additionally detected the serum concentration of three traditional biomarkers-carcinoembryonic antigen (CEA), cancer antigen (CA)-125, and cytokeratin 19 fragments (Cyfra 21-1)-to comparatively evaluate the efficiency and diagnostic value of VEGF in patients with NSCLC.We further evaluated the relationship between serum VEGF levels and clinicopathologic parameters.VEGF levels were compared between pro-and post-surgical patients using the Wilcoxon matched-pairs signed-rank test.DNA was isolated from the primary tumors.EGFR mutations were detected by Scorpions amplification refractory mutation system (ARMS).Results: Patients with NSCLC had significantly higher serum concentration of VEGF, compared to those with benign pulmonary nodules and healthy controls (P <0.0001).As a diagnostic biomarker of NSCLC, VEGF had area under the curve values of 0.824 and 0.839, sensitivities of 75.0% and 75.0%, and specificities of 93.3% and 95.6% when compared with healthy people and patients with benign pulmonary nodules, respectively; notably, these values were greater than those of CA125, Cyfra 21-1 and CEA.Furthermore, a model in which VEGF was combined with CEA, CA125, and Cyfra 21-1 was more effective for NSCLC diagnosis than VEGF alone (sensitivity, 85.0% and 84.4; specificity, 90.0% and 91.9% vs. healthy controls and patients with benign pulmonary nodules, respectively).When use to identify early-stage NSCLC, VEGF showed a better diagnostic efficacy than other biomarkers.The pro-surgical VEGF levels were significantly higher than those measured 25-30 days after surgery.Moreover, VEGF concentration differed significantly among cases according to TNM stages and malignant grades (P <0.0001).EGFR mutations and the size of benign pulmonary nodules did not affect the level of serum VEGF significantly.Conclusion: The serum VEGF levels exhibited relatively high sensitivity and specificity for NSCLC, and may therefore be a useful diagnostic biomarker.Furthermore, the serum VEGF levels could be used to assess prognosis and curative effects.
Open the resolved locator · 10.7150/jca.23973
Metadata licence: OpenAlex metadata (CC0)